Background: Monocyte subsets are not well defined in murine peripheral blood (PB). Monocyte-related populations could also be located in bone marrow (BM), but studies correlating monocyte populations found in these two tissues are lacking. This study simultaneously analyzed PB and BM to phenotypically define multiple monocyterelated subsets in each location. Methods: Murine PB and BM cells were simultaneously stained for monocyte-related populations, using five-color flow cytometry. Relevant subsets were defined on the basis of Ly-6C, CD11b, and wheat germ agglutinin phenotype in addition to light-scatter characteristics. These populations were extensively characterized for the expression of other myeloid and dendritic cell markers, adhesion molecules, chemokine receptors, and growth factor receptors. Results: Six monocyte-related populations were defined,
High dose therapy followed by autologous stem cell rescue for the treatment of multiple myeloma has been shown to be associated with improved outcome including increased complete response rates and survival. It is unclear what role, if any, autologous dendritic cell (DC) reconstitution patterns play in determining outcome. DC in peripheral blood (PB) can be divided into two subsets: DC1, which favor Th1 responses and DC2, which favor Th2 responses and in some cases appear to be immunosuppressive. In this companion study to a tandem stem cell transplant research protocol, PB DC subsets were studied prior to the administration of mobilizing chemotherapy (baseline), at the time of stem cell collection, on the day of transplant and at post transplant d. 15, 30, 60, and 90 following the first transplant. GM-CSF was used as part of the mobilization regimen as well as to enhance neutrophil recovery post-transplant. DC were identified as lineage (CD3/14/16/19) negative, HLA-DR+. Of these cells, DC1 were identified as CD11c+CD123− or CD33hiCD4lo, and DC2 were identified as CD11c−CD123+ or CD33lo/−CD4+. Sixteen patients have been enrolled and 11 are at least 90 d. post transplant #1. Median followup time is 12 months (range 7–25 months). 5 patients currently are in complete remission, 3 have had partial responses, 2 have stable disease, and 1 died of recurrent disease. In most cases, DC1 counts were higher than DC2 counts at all time points examined. At baseline, this was true for 77% of patients, indicating at baseline most patients maintain the higher DC1 numbers found in healthy humans. DC numbers increased in mobilized PB, and correlated well with the patients’ baseline counts. GM-CSF was more efficient at increasing DC2 than DC1, as has been reported for G-CSF. Post-transplant, DC recovery to at or near baseline levels occurred in most patients by d. 60. There was a trend for patients who are currently disease-free and those with partial responses to have a lower DC1:DC2 ratio (i.,e., DC2 reconstitution occurred more vigorously than DC1 reconstitution). The patient who died of progressive disease had the highest DC1 counts at several time points, and among the lowest DC2 counts leading to a consistently high DC1:DC2 ratio at 30, 60, and 90 days post-transplant. This finding suggests that in autologous transplant for multiple myeloma, proportionately increased numbers of DC2 are not associated with an increased risk of relapse, as was previously reported for allogeneic bone marrow transplant, but instead are associated with an improved likelihood of complete remission. Mobilization with a growth factor that favors the DC2 subset, such as GM-CSF, may promote the post-transplant production of a DC population that is able to assist in maintaining a complete response to high dose chemotherapy. If these trends are maintained upon final analysis of the patient population, additional means of selectively increasing DC2 numbers in this transplant setting would warrant further investigation.
High dose therapy followed by autologous stem cell rescue for the treatment of multiple myeloma has been shown to be associated with improved outcome including increased complete response rates and survival. It is unclear what role, if any, autologous dendritic cell (DC) reconstitution patterns play in determining outcome. DC in peripheral blood (PB) can be divided into two subsets: DC1, which favor Th1 responses and DC2, which favor Th2 responses and in some cases appear to be immunosuppressive. In this companion study to a tandem stem cell transplant research protocol, PB DC subsets were studied just prior to the administration of mobilizing chemotherapy (baseline), at the time of stem cell collection, and on transplant d. 0, 15, 30, 60, and 90 following the first and second transplants. DC were identified as lineage (CD3/14/16/19) negative, HLA-DR+. Of these cells, DC1 = CD11c+CD123− or CD33hiCD4lo, and DC2 = CD11c−CD123+ or CD33lo/−CD4+. Precursor DC numbers (Pre-DC1 = CD45loCD34+HLA-DR+CD86+; Pre-DC2 = CD45loCD34+HLA-DR+CD10+) were also assessed in the stem cell products. GM-CSF (sargramostim) was used as part of the mobilization regimen as well as to enhance neutrophil recovery post-transplant. Twenty patients were enrolled and all are >90 d. post transplant #1. Six patients received a 2nd transplant. Median followup time is 25 months (range 3–56 months). Seven patients are in complete remission (CR), 7 have had a partial response, 4 have progressive disease, and 2 died of recurrent disease. In most cases, DC1 counts were higher than DC2 counts at all time points examined. At baseline, this was true for 70% of patients, indicating that immediately prior to transplant most patients maintain the DC1>DC2 ratio found in healthy humans. DC subset numbers generally increased over baseline in mobilized PB, and correlated well with the patients’ baseline DC counts. Similarly, baseline DC subset numbers were highly correlated (R>0.7) with the number of pre-DC1 or pre-DC2 found in the stem cell products. No patients with pre-DC1<pre-DC2 achieved a CR. Post-transplant, DC1 recovery to baseline levels occurred in most patients by d. 60. DC2 recovery was often more rapid, with baseline levels reached in many patients at d. 30. Patients who had high (>10/ul) PB DC1 numbers at d. 90 consistently remain in CR. This study is the first to systematically examine DC subset reconstitution following autologous transplant for multiple myeloma. Our results provide preliminary evidence that the presence of high numbers of PB DC1 at d. 90 may predict a good long term prognosis, perhaps by promoting an effective endogenous immune response against residual disease. Furthermore, pre-DC1<pre-DC2 in the stem cell product might predict a poor outcome, and increase early consideration of post-transplant adjunctive therapy. As GM-CSF is known to mobilize proportionately more DC1 (relative to DC2) than G-CSF (Vela-Ojeda 2006, Ann Hematol 85:308–14), use of GM-CSF may provide a long-term disease free benefit in addition to facilitating stem cell collection and limiting post-transplant neutropenia in patients with multiple myeloma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.